Abstract: Many G5-Iinked receptors have been reported to use multiple signalling pathways in transfected cells but few in their normal cell environment. We show that the adenosine A2a receptor uses two signalling pathways to increase the release of acetylcholine from striatal nerve terminals. One pathway involves activation of G5, adenylyl cyclase, protein kinase A, and P-type calcium channels; the other is mediated by a cholera toxin-insensitive G protein, protein kinase C, and N-type calcium channels. The effects of these two pathways are not additive, the second pathway being inhibited by the first; but they are equally sensitive to the A2a receptor antagonist KF1 7837. This demonstrates that the A2a receptor activates two signalling systems in striatal cholinergic neurons. Key Words: G5 protein-linked receptor-Adenosine A2a receptor-Signalling pathway-Acetylcholine-A2a receptor antagonist-KF1 7837.
Adenosine is a potent modulator of neurotransmitter release (Fredhoim and Dunwiddie, 1988) , exerting its actions via four major receptor subtypes, I, A~a,A2b, and A3, which have been characterized according to their pharmacological profile, their effects on adenylyl cyclase, and their primary sequences (see Fredhoim et a!., 1994) .
In the CNS, A2a receptors are concentrated in the striatum, the nucleus accumbens, olfactory tubercie, and the lateral segment of the globus pallidus (Jarvis et a!., 1989; Parkinson and Fredhoim, 1990; MartinezMir et a!., 1991; James et al., 1992) . In these areas, this receptor stimulates acetylcholine release (Brown et a!., 1990; Jin et al., 1993; Kirkpatrick and Richardson, 1993; Kirk and Richardson, 1994; Kurokawa et al., 1994) and can either stimulate (Mayfield et a!., 1993) or inhibit GABA release. In behavioural tests, A2a receptor agonists antagonize the effects of dopamine receptor activation (Brown et a!., 1991; Vellucci et a!., 1993) , suggesting that A2a receptor antagonists may be useful in the therapy of Parkinson's disease.
Adenosine A2a receptors are coupled to a G. U protein (Marala and Mustafa, 1993) and have been shown to activate adenylyl cyclase (Brown et a!., 1990; Lupica et a!., 1990) . However, the inhibition of GABA release from striatal nerve terminals has been shown to be independent of cyclic AMP (cAMP) and protein kinase A activity (Kirk and Richardson, 1995b) , suggesting that this receptor may use more than one effector mechanism. Other G5-linked receptors have been reported to use a number of different effector mechanisms within cells (Yatani et a!., 1988; Birnbaumer, 1992; , although most demonstrations of such multiple signalling have utilized transfected cell lines, to reduce complications arising from the possible action of multiple receptors within normal tissues. However, the ability of a receptor to recruit a given effector system depends in part on the nature and abundance of the G proteins and effectors present within the cells being studied. Consequently, it is important to examine the possible use of multiple signalling pathways by specific receptors in the cells in which they are normally expressed. We have investigated the signalling pathways used by the adenosine A2a receptor in its normal cellular environment, and report the existence of two separate but interacting pathways stimulated by this receptor in striatal cholinergic nerve terminals.
EXPERIMENTAL PROCEDURES

Preparation of striatal synaptosomes
Striatal nerve terminals (synaptosomes) were prepared from Wistar rats by the Percoll method of Verhage et al. (1989) , as previously described , and suspended in 20 ml of the following loading buffer (mM): NaCl (125), KC1 (4.75) , MgC12 (1.4), CaC!2 (2), HEPES (20, pH 7.4), eserine(0.l), and glucose (10). The nerve terminals were then recentrifuged at 15,000 rpm for 20 mm at 4°C.Synaptosomal pellets were stored on ice for up to 3 h before use.
Release of radiolabelled acetyicholine and choline
The modulation of acetyicholine release was performed as described by Kirk and Richardson (1994) . Before loading, synaptosomes were resuspended in 4 ml of fresh loading buffer to give a final protein concentration of 0.5-1.5 mg/ ml and then incubated with I~M [methyl- 3H] choline chloride (2.5~tCiml ')for 30 mm at 37°C.In some experiments, cholera toxin (2~.sg/ml) was included in this 30-mm incubation. After radiolabelling, the synaptosomes were diluted 1:4 with perfusion buffer of the following composition (mM):
(1.2), CaCl2 (1.2), glucose (10), at 37°Cand continuously gassed with 95% 02 and 5% CO2.
The synaptosomal suspension was then drawn onto a series of eight parallel perfusion chambers containing Whatman GF/B filters and superfusion started at a rate of 0.5 ml! mm. The perfusion chambers and buffer were maintained at 37°Cand the buffer aerated (bubbled with 95% 02/5% C02) throughout. After an equilibration period of 30 mm, adenosine deaminase (5 U/mi) was added to the perfusion buffer and the synaptosomes superfused for afurther 10 mm. Thereafter, superfusate samples were collected at 2-mm intervals into scintillation vials containing 10 ml of emulsifier safe scintillant for radiometric counting. Release of [ 3H]-acetylcholine was evoked by depolarizing the synaptosomes twice (spaced 16 mm apart) for 90 s with perfusion buffer containing high potassium (15 mM). Whereas the first period of stimulation (S 1) always contained elevated potassium concentrations (15 mM) alone, the second stimulation period (S2) was either high potassium alone (control) or with the agents under investigation. All agonists were added to the perfusion medium concomitantly with the depolarizing stimulus, whereas the antagonists, and the calcium channel blockers, were perfused over the synaptosomes 6 mm before, and during, the depolarization. The evoked release for each stimulus was expressed as a percentage of the total amount of radiolabel present in the synaptosomes at the point at which the release was evoked, and was calculated by subtracting basal release from total release for each stimulus. Modulation of release was assessed by changes in the ratio of the 3H-Iabel released between the two stimuli (i.e., S 2/Sr atio). Experimental controls, in which both stimuli contained elevated KC1 alone, were always run in parallel, the mean control S2IS ratio varied in the experiments described between 0.66 and 0.82. When the nerve terminals had been
FIG. 1. Perfusion profile of~3
H]acetylcholine release from rat striatal nerve terminals. Nerve terminals were perfused as described and release stimulated by the inclusion of 15 mM KCI in the perfusion buffer for 90 s.
pretreated with cholera toxin, the background release of label was much greater, which necessitated the analysis being performed on the first stimulus alone. The nature of the released radioactivity in this system has been shown to be >75% acetylcholine .
Drugs and chemicals
Adenosine deaminase (type VII), 8 bromo cAMP, forskolin, I ,9-dideoxyforskolin, cholera toxin, and eserme (physostigmine) were obtained from Sigma. 
RESULTS
Rat striatal nerve terminals were perfused and the ability of selected agents to modify the potassiumevoked release of [3H]acetylcho!ine assessed using a standard dual stimulation protocol (Fig. 1) . A change in the ratio of released acetyicholine in the two stimuli (S 2/S1), caused by the presence of an agonist in S2, when compared with control perfusions without the agonist, is evidence of a modulation of the release process. In this system, we have already shown that addition of the A2a receptor selective agonist CGS 21680 (0.1 nM) is sufficient to produce the maximal increase in acety!choline release and that this stimulation is sensitive to the A2a receptor antagonist KF17837, but not to the A1-selective antagonist DPCPX (Kurokawa et a!., 1994) . In addition, there is no detectable influence of endogenously released transmitters on the nerve terminals present in this perfusion system (Kurokawa et al., 1994) . In initial experiments, the effect of the A2a receptor- CGS 21680, forskolin, and 8-bromo cAMP were present only during the second stimulus (S2); HAIOO4 was added 6 mm before, and during, this stimulus. Results are mean ±SEM values of three or four experiments, each containing duplicate determinations. Percentages ofchanges are given only where the S2/S, ratios were significantly different from the relevant control. "Significant difference from the control (15 mM KCI alone) (p < 0.01, Students t test).
Significant difference from HA 1004 alone (p < 0.01).
selective agonist CGS 21680 (Jarvis et al., 1989 ) on calcium-dependent and independent release was examined. As shown in Table 1 , the absence of calcium from the perfusion medium resulted in an '-"70% reduction in [ 3H I acetyicholine release. The A 2. receptor affected only exocytotic (calcium dependent) release, because inclusion of 0.1 nM CGS 21680 in the second stimulus increased the release by 24% in the presence of extracellular calcium but had no effect in its absence. Because the A2a receptor stimulates adenylyl cyclase in many systems, we examined the possible role of cAMP in the control of acetylcholine release. As expected, the permeant cAMP analogue 8-bromo cAMP (1 mM) and the adenylyl cyclase activator forskolin (2 1iM), when present during the second stimulus, increased the evoked release of [ 3Hlacetylcholine (Table 1) . However, although the protein kinase A inhibitor HA1004 (10~.tM) blocked the ability of forskolin to enhance { 3H I acetylcholine release, it had no effect on the stimulation of release by CUS 21680. In the presence of forskolin, CGS 21680 (0.1 nM) was unable to further increase the release of [3H]-acetylcholine. I ,9-Dideoxyforskolin (2 1iM), a derivative that does not stimulate adenylyl cyclase, did not enhance the evoked release (Table I) , and CGS 21680 (0.1 nM) was able to increase significantly the release of labelled acetylcholine in its presence.
Because HA 1004 had no effect on the stimulation by the A2. receptor, the effect of other protein kinase inhibitors was examined. H-7 (30 bIM), a nonselective inhibitor of protein kinases, abolished the increase of release induced by CUS 21680 (Fig. 2) . As with HA!004, the protein kinase C inhibitor chelerythrine alone did not diminish this stimulation. However, si- acetyicholine, and the effect of HAIOO4 on evoked release in a single stimulus was examined. Cholera toxin pretreatment caused a 34% increase in the potassium-evoked release of acetyicholine, compared with nerve terminals not treated with the toxin (p < 0.05, Table 2 ). This effect was reversed completely by HA 1004, and inclusion of chelerythrine with HA 1004 had no further inhibitory effect (Table 2 ). This demonstrated that the increased release of acetylcholine, after the stimulation of U. by this toxin, was mediated by protein kinase A but not protein kinase C.
The effect of selective calcium channel blockers was also investigated as the A 2,, receptor only potentiated calcium-dependent release. Neither the L-type calcium channel blocker nifedipine (0.1 mM) nor the N-type calcium channel blocker w-conotoxin (0.5 ,uM) had any effect on the CGS 21680-induced increase in [ 3H]acetylcholine release (Fig. 3) . In contrast, the Ptype channel blocker w-agatoxin (10 nM), although having little effect on the evoked release, abolished completely the effect of CGS 21680 (Fig. 3) .
To investigate whether both protein kinases A and C mediated their effects through the P-type channel, the effect of w-agatoxin on A 2,, receptor-stimulated release in the presence of chelerythrine was examined, i.e., when the receptor-stimulated release was mediated by protein kinase A. As shown in Fig. 4 , w-agatoxin inhibited the stimulation of release induced by the A2,, receptor under these conditions. However, when the action of the A2a receptor was examined in the presence of HA1004, w-conotoxin, but not w-agatoxin, abolished the stimulation (Fig. 4) . Consequently, the stimulation of release mediated by protein kinase A was blocked by the P-type channel blocker and the stimulation mediated by protein kinase C was inhibited by the N-type calcium channel blocker (see Fig. 6 ). The effect of nifedipine in the presence of HA 1004 was not examined. Under the experimental conditions of this study, in the absence of calcium channel blockers and protein kinase inhibitors, the potentiation of release by CGS 21680 was mediated principally by the protein kinase A/P-type channel pathway, because it was sensitive to w-agatoxin (Fig. 3) .
It was conceivable that the two signalling pathways stimulated by CGS 21680 were mediated by two separate receptors, so the effect of the A2a receptor-selective antagonist KF17837 was investigated in the presence and absence of HA 1004. There was no significant difference in the ability of this antagonist to block the
FIG. 4.
The action of the A 2,, receptor is mediated by P-type calcium channels when protein kinase C is inhibited and by Ntype calcium channels when protein kinase A is inhibited. The stimulation of [ 3H}acetylcholine release (open columns) by 0.1 nM CGS 21680 (filled columns) was blocked by the P-type calcium channel blocker w-agatoxin (10 nM) when protein kinase C was inhibited by chelerythrine (6 jiM), and by the N-type calcium channel blocker w-conotoxin (0.5 jiM) when protein kinase A was inhibited by HA1004 (10 jiM). Results enhancement of acetylcho!ine release induced by CGS 21680, in the presence or absence of HAIOO4 (Fig.  5) . These data are consistent with the adenosine A2,, receptor stimulating the release of acety!cholineby two separate effector pathways triggered by different U proteins; an outline of the pathways is shown in Fig. 6 .
DISCUSSION
In the experiments described in this study, the A2,, receptor agonist CGS 21680 stimulated potassiumevoked, calcium-dependent acetylcholine release by 29 ± 1% (n = 25). Because calcium-dependent release amounted to 70% of the total, this corresponds to an average increase of 41% in the exocytotic release of acety!cho!ine.
The adenosine A~,receptor stimulates two protein kinases
Because we have previously shown that the adenosine A2,, receptor stimulates adenyly! cyclase in striata! cholinergic synaptic membranes (Brown et a!., 1990 ), we first examined the possible role of cAMP in the stimulation of acety!choline release. As shown in Table  1 , the potentiation of release by the adenyly! cyclase activator forskolin was blocked by the protein kinase A inhibitor HA 1004 (K, of 2 and 40 ,uM at protein kinases A and C, respectively; Hidaka et a!., 1984), although the stimulation of release by the A2,, receptor agonist CGS 21680 was unaffected. This suggested that this receptor may not act solely via cAMP-induced increases in the activity of protein kinase A. However, the nonse!ective protein kinase inhibitor H-7 abolished the stimulation by the A2a receptor, as did the coapplication of HA 1004 and the protein kinase C inhibitor che!erythrine (Herbert et a!., 1990) . In these experiments, A2,, receptor activation was therefore mediated exclusively by protein kinases A and C. Because the A2,, receptor was unable to increase release in the presence of forsko!in (Table 1) , and because neither protein kinase inhibitor alone had a significant effect on the action of the A2,, receptor, it appeared that stimulation of the two kinases did not have an additive effect on acety!choline release. This indicates that the A2,, receptor-sensitive kinases were not present in separate cholinergic nerve terminal populations.
The adenylyl cyclase, protein kinase A, and P-type calcium channel pathway
Having established that the A2a receptor operated by the stimulation of two protein kinases, the ability of G, to stimulate these kinases was investigated. As shown in Table 2 , permanent activation of U. by cholera toxin increased acety!cho!ine release, in a manner reversed by HA1004. This is similar to the result obtained with forskolin stimulation of adenyly! cyclase ( Table 1 ) and demonstrates that U, activation increased acetylcho!ine release via protein kinase A but not protein kinase C.
Low concentrations (10 nM) of the P-type blocker w-agatoxin IVA abolished completely the A2,, receptor-mediated stimulation of acety!cho!ine release in the presence of chelerythrine (Fig. 4) , without affecting potassium-evoked release. Thus, when the receptor acted by stimulating protein kinase A, P-type calcium channels mediated the increase in release. A similar sensitivity to w-agatoxin was seen under normal conditions (i.e., in the absence of kinase inhibitors), suggesting that the protein kinase A/P-type calcium channel pathway normally mediated the effect of A2,, receptor stimulation. The modulation of P-type channels by receptors has been observed in several nerve terminals including an adenosine A2 receptor-induced stimulation in the rat brainstem (Umemiya and Berger, 1994) and a probable adenosine A2b receptor-mediated stimulation in hippocampa! CA3 neurons (Mogul et al., 1993) . Indeed, it appears that P-type calcium channels may be the major voltage-sensitive channel inducing nerve terminal transmitter release in the CNS (see, e.g., Luebke et a!., 1993; . Consensus phosphorylation sites for protein kinase A are present in most calcium channel sequences (Dube! et al., 1991; Mon et al., 1991; Snutch eta!., 1991) , and the observation made here that protein kinase A activation enhances release is consistent with previous observations that phosphorylation of the P-type channel is likely to increase the calcium current (Mogul et a!., 1993) .
The protein kinase C/N-type calcium channel pathway
The increase in acetylcho!ine release in the presence of HA1004 was blocked not only by chelerythrine (Fig. 2) , but also by w-conotoxin (Fig. 3) . Thus, when the receptor acted via protein kinase C (i.e., when protein kinase A was blocked by HA 1004), N-type calcium channels mediated the enhancement of acetylcholine release. The P-type channel was not involved because w-agatoxin had no effect under these conditions (Fig. 4) . The modulation of both whole cell (e.g., Zhu and Ikeda, 1993) and nerve terminal N-type calcium channels has been previously reported. For example, adenosine A1 receptors inhibit N-type channels in glycinergic nerve terminals (Umemiya and Berger, 1994) , and the A2,, receptor in the striatum may act in a similar manner to inhibit GABA release (Kirk and Richardson, 1995b) . Protein kinase C has also been implicated in the control of this channel in other systems (Boland et a!., 1991; Yang and Tsien, 1993; Diversé-Pierluissi et al., 1995 ). The precise mechanism by which protein kinase C potentiates the N-type channel in these nerve terminals is not known; direct phosphorylation or a reduction in an inhibitory effect on the ion channel may be involved (Swartz, 1993) .
The presence of both N-and P-type calcium channels in the same nerve terminal population has been observed in other systems, e.g., cholinergic synapses of Aplysia (Fossier eta!., 1994) and Torpedo (Moulian and Uaudry-Talarmain, 1993) , as well as glutamatergic nerve terminals of the hippocampus (Luebke et al., 1993; Castillo et al., 1994) .
The interaction between the two pathways
As noted above, it is unlikely that the two effector pathways identified operate in separate populations of nerve terminals because partial inhibition of the A2a receptor potentiation was not observed with chelerythrifle (Fig. 2 ) nor with HA1004 (Table I) , and CUS 21680 was ineffective in the presence of forskolin (Table 1). In addition, w-agatoxin abolished completely the potentiation, suggesting that under the normal conditions of these experiments, the P-type channel, activated by protein kinase A, was the major effector system of the A2a receptor in all striatal cholinergic nerve terminals. Protein kinase C and the N-type calcium channel were not involved in the A2,, receptor response under these conditions (Figs. 2 and 3) ; it was not until the protein kinase A blocker HA 1004 was added that the protein kinase C-stimulated N-type calcium channel became apparent. This was not due simply to a greater activity of the protein kinase A/P-type channel pathway, because blockade of the P-type channel with w-agatoxin did not reveal the protein kinase C/N-type channel pathway, unless HA1004 was also present (Fig. 4) . Therefore, protein kinase A inhibited the protein kinase C/N-type channel pathway.
Dual signalling by the A2a receptor
Cholera toxin was able to stimulate acetylcholine release via the protein kinase A pathway but not the protein kinase C pathway, demonstrating that the two pathways have different sensitivities to the toxin and suggesting that different U protein(s) may be involved in the two pathways. It is therefore possible that the two signalling pathways described here are stimulated by two distinct receptors, one of which activates U,, adenylyl cyclase, and protein kinase A, whereas the other may activate a member of the Uq U protein family, phospholipase C and protein kinase C. However, both pathways were stimulated by the same concentration of the 140-fold A2,, receptor-selective agonist CUS 21680, and were blocked by the same concentration of the 50-fold selective A2,. receptor antagonist KF17837 (Nonaka et al., 1994) . In addition, the A1 receptor inhibits striatal acetylcholine release (Richardson et al., 1987; Brown et al., 1990; Kirk and Richardson, 1994) , and the stimulation of acetylcholine release is insensitive to the A1 antagonist DPCPX (Kurokawa et al., 1994) , so it is extremely unlikely that the A1 receptor was involved. Because CGS 21680 does not bind to A2b (Yake! et a!., 1993) receptors, and because the A3 receptor exhibits low affinities for both xanthine antagonists and CGS 21680 (Van Ualen et a!., 1994), it appears that the recruitment of the two signalling pathways was not due to the involvement of more than one of the cloned adenosine receptors. Currently, there is little evidence for the presence of an A2,, receptor other than the one that has been cloned (Kirk and Richardson, 1995 a) , and there is recent evidence from in situ hybridization for the expression of this receptor in striatal cholinergic neurons (A. K. Dixon et al., unpublished data). Although it is impossible to disprove the presence of two A2,,-!ike receptors in these nerve terminals, the available evidence suggests that only the cloned receptor is present and that this receptor activates U. and another U protein, probably of the Uq type. Another cAMP-independent signalling pathway used by the A2,, receptor has been observed in striatal UABA nerve terminals, although this probably involves inhibition of an N-type channel rather than a stimulation (Kirk and Richardson, 1 995b) . A similar pathway has been described by Zhu and Ikeda (1994) for the U,-!inked vasoactive intestinal peptide receptor.
There is already considerable evidence for U,-linked receptors stimulating diverse effector systems including L-type calcium channels (Yatani et al., 1988) , adenylyl cyclase, and phospholipase C . However, to exclude the complications inherent in studies of tissues containing two or more similar receptors, these studies have been performed using the expression of cloned receptors in cell lines (e.g., Van Sande et a!., 1990; Gudermann et al., 1992; Liu et a!., 1992) . In general, it appears that G,-linked receptors need to be expressed at high density to stimulate phospholipase C . However, as different receptor densities are required to activate different effector pathways in different cell lines (e.g., Liu et a!., 1992) , it is probable that the G protein content of the cell lines used also influences the recruitment of effector systems. In striata! cholinergic nerve terminals, it appears that the receptor density is sufficient to activate two pathways, even when the agonist is present at <1% of its KD value at the A 2,, receptor (15 nM; Jarvis et al., 1989) .
In conclusion, we have demonstrated the presence of two separate signalling pathways for the A2,, receptor in the same population of striatal cholinergic nerve terminals, involving two G proteins, two protein kinases, and two types of voltage-sensitive calcium channel. These two pathways, activated by a receptor usually thought to be only linked to G,, are interactive, with one pathway regulating the activity of the other. Overexpression of the receptor was not required for the second effector pathway to be recruited. These two pathways may be present to permit this receptor to increase acety!cho!ine release even when adenylyl cyclase is inhibited by other modulators, including adenosine (via the A1 receptor) and dopamine.
